Friday, 16 October 2026European Markets

TELEPERFORMANCE Stock Slides 9% So Far On Thursday, Underperforms Market

Loading stream...

teleperformance's shares experienced a significant 9.68% downfall during thursday's trading session, closing at eur142.80 after two consecutive sessions of gains. this occurred while the cac 40 index rose by 1.42%, ending its three-day decline. the individualized fall in teleperformance's share value suggests that the reasons behind this may be specific to the company, rather than being a result of a broader market trend.

company performance overview

marking the latest closing, teleperformance's share price was at eur158.50. this is a decline by 52.43% from its 52-week high of eur333.20 but is still above the company's 52-week low of eur137.30. this could be a positive indication for those investors who focus on the longer-term.

services and business operations

teleperformance provides a diverse range of services, encompassing both core services and digital integrated business services, along with specialized services. the latter includes solutions such as data analysis, customer acquisition, and government agency outsourcing among others.

financial indicators

in terms of its financial performance over the last year, the company has reported an earnings per share (eps) of eur10.81, along with an earnings-to-price (e/p) ratio of 13.21. this suggests that an investor would need to invest eur13.21 to earn one euro from the company's earnings each year, indicating a reasonable level of valuation.

return on equity

over the previous twelve months, teleperformance's return on equity (roe) was at 18.89%, which displays healthy profitability levels relative to shareholder's equity. however, the recent fall in share prices needs to be closely monitored. it will help determine whether this is solely a market hiccup or a reflection of deeper issues in the company's business operations.

more news about teleperformance (tep.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com